These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Anticytokine therapy impacting on B cells in autoimmune diseases. Daridon C; Burmester GR; Dörner T Curr Opin Rheumatol; 2009 May; 21(3):205-10. PubMed ID: 19346949 [TBL] [Abstract][Full Text] [Related]
5. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. Perosa F; Prete M; Racanelli V; Dammacco F J Intern Med; 2010 Mar; 267(3):260-77. PubMed ID: 20201920 [TBL] [Abstract][Full Text] [Related]
6. Targeting B cells with biologics in systemic lupus erythematosus. La Cava A Expert Opin Biol Ther; 2010 Nov; 10(11):1555-61. PubMed ID: 20919800 [TBL] [Abstract][Full Text] [Related]
7. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases. Tanaka Y Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614 [No Abstract] [Full Text] [Related]
8. New therapies in development for autoimmune diseases: their rationale for combination treatment. Strand V Springer Semin Immunopathol; 2001; 23(1-2):43-61. PubMed ID: 11455860 [No Abstract] [Full Text] [Related]
9. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Murdaca G; Colombo BM; Puppo F Autoimmun Rev; 2011 Nov; 11(1):56-60. PubMed ID: 21835271 [TBL] [Abstract][Full Text] [Related]
11. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases]. Tanaka Y Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410 [TBL] [Abstract][Full Text] [Related]
12. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Liang B; Gardner DB; Griswold DE; Bugelski PJ; Song XY Immunology; 2006 Nov; 119(3):296-305. PubMed ID: 17067309 [TBL] [Abstract][Full Text] [Related]
13. New treatments for SLE: cell-depleting and anti-cytokine therapies. Anolik JH; Aringer M Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):859-78. PubMed ID: 16150407 [TBL] [Abstract][Full Text] [Related]
14. B cell immunotherapy in autoimmunity--2010 update. Chan AC Mol Immunol; 2011 Jun; 48(11):1344-7. PubMed ID: 21194752 [TBL] [Abstract][Full Text] [Related]
15. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases]. Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605 [TBL] [Abstract][Full Text] [Related]
16. CD20: a target antigen for immunotherapy of autoimmune diseases. Perosa F; Favoino E; Caragnano MA; Prete M; Dammacco F Autoimmun Rev; 2005 Nov; 4(8):526-31. PubMed ID: 16214090 [TBL] [Abstract][Full Text] [Related]
17. [New strategies in the immunotherapy of autoimmune diseases]. Lorenz HM; Geiler T Dtsch Med Wochenschr; 2001 Sep; 126(37):1023-8. PubMed ID: 11555778 [No Abstract] [Full Text] [Related]
18. The immunological basis of B-cell therapy in systemic lupus erythematosus. Mok MY Int J Rheum Dis; 2010 Feb; 13(1):3-11. PubMed ID: 20374380 [TBL] [Abstract][Full Text] [Related]
19. Bispecific antibody fragments with CD20 X CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma. Brandl M; Grosse-Hovest L; Holler E; Kolb HJ; Jung G Exp Hematol; 1999 Aug; 27(8):1264-70. PubMed ID: 10428503 [TBL] [Abstract][Full Text] [Related]
20. Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases. Pers YM; Jorgensen C Immunotherapy; 2016 Sep; 8(9):1091-6. PubMed ID: 27485081 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]